Document:

Exhibit 10.2

 

INTELLECTUAL PROPERTY SECURITY AGREEMENT

 

This Intellectual
Property Security Agreement (“Agreement”) is entered into as of the Effective Date by and between Eastward Fund Management,
LLC (“Lender”) and Augmedix, Inc. (“Grantor”).

 

RECITALS

 

A. Lender
has agreed to make certain advances of money and to extend certain financial accommodation to Grantor and Grantor’s
subsidiary (the “Loans”) in the amounts and manner set forth in that certain Loan and Security Agreement by and
between Lender, Grantor and Grantor’s subsidiary, Augmedix Operating Corporation, dated the Effective Date (as the same
may be amended, modified or supplemented from time to time, the “Loan Agreement”; capitalized terms used herein
are used as defined in the Loan Agreement). Lender is willing to make the Loans to Grantor, but only upon the condition,
among others, that Grantor shall grant to Lender a security interest in certain Copyrights, Trademarks, Patents, and Mask
Works (as each term is described below) to secure the obligations of Grantor under the Loan Agreement.

 

B. Pursuant
to the terms of the Loan Agreement, Grantor has granted to Lender a security interest in all of Grantor’s right, title and
interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

 

NOW, THEREFORE,
for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral
security for the prompt and complete payment when due of its obligations under the Loan Agreement, Grantor hereby represents, warrants,
covenants and agrees as follows:

 

AGREEMENT

 

1. Grant
of Security Interest. To secure its obligations under the Loan Agreement, Grantor grants and pledges to Lender a security
interest in all of Grantor’s right, title and interest in, to and under its intellectual property (all of which shall
collectively be called the “Intellectual Property Collateral”), including, without limitation, the
following:

 

(a) Any
and all copyright rights, copyright applications, copyright registrations and like protections in each work or authorship and
derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, now or
hereafter existing, created, acquired or held, including without limitation those set forth on Exhibit A attached
hereto (collectively, the “Copyrights”);

 

(b) Any
and all trade secrets, and any and all intellectual property rights in computer software and computer software products now or
hereafter existing, created, acquired or held;

 

(c) Any
and all design rights that may be available to Grantor now or hereafter existing, created, acquired or held;

 

     

     

    

 

(d) All
patents, patent applications and like protections including, without limitation, improvements, divisions, continuations, renewals,
reissues, extensions and continuations-in-part of the same, including without limitation the patents and patent applications set
forth on Exhibit B attached hereto and any patents and patent applications claiming the priority benefit of the patents
and patent applications set forth on Exhibit B attached hereto (collectively, the “Patents”);

 

(e) Any
trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections,
and the entire goodwill of the business of Grantor connected with and symbolized by such trademarks, including without limitation
those set forth on Exhibit C attached hereto (collectively, the “Trademarks”);

 

(f) All
mask works or similar rights available for the protection of semiconductor chips, now owned or hereafter acquired, including, without
limitation those set forth on Exhibit D attached hereto (collectively, the “Mask Works”);

 

(g) Any
and all claims for damages by way of past, present and future infringements of any of the rights included above, with the right,
but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified
above;

 

(h) All
licenses or other rights to use any of the Copyrights, Patents, Trademarks, or Mask Works and all license fees and royalties arising
from such use to the extent permitted by such license or rights;

 

(i) All
amendments, renewals and extensions of any of the Copyrights, Trademarks, Patents, or Mask Works; and

 

(j) All
proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty
payable in respect of any of the foregoing.

 

2. Recordation.
Grantor authorizes the Commissioner for Patents, the Commissioner for Trademarks and the Register of Copyrights and any other government
officials to record and register this Agreement upon request by Lender.

 

3. Authorization.
Grantor hereby authorizes Lender, upon prior written notice to Grantor to (a) modify this Agreement solely by amending the exhibits
to this Agreement to include any Intellectual Property Collateral which Grantor obtains subsequent to the date of this Agreement,
and (b) file a duplicate original of this Agreement containing amended exhibits reflecting such new Intellectual Property Collateral.

 

4. Loan
Documents. This Agreement has been entered into pursuant to and in conjunction with the Loan Agreement, which is hereby incorporated
by reference. The provisions of the Loan Agreement shall supersede and control over any conflicting or inconsistent provision
herein. The rights and remedies of Lender with respect to the Intellectual Property Collateral are as provided by the Loan Agreement
and related documents, and nothing in this Agreement shall be deemed to limit such rights and remedies.

 

    2

     

    

 

5. Execution
in Counterparts. This Agreement may be executed in counterparts (and by different parties hereto in different counterparts),
each of which shall constitute an original, but all of which when taken together shall constitute a single contract. Delivery of
an executed counterpart of a signature page to this Agreement by facsimile or in electronic (i.e., “pdf” or “tif”
format) shall be effective as delivery of a manually executed counterpart of this Agreement.

 

6. Successors
and Assigns. This Agreement will be binding on and shall inure to the benefit of the parties hereto and their respective successors
and assigns.

 

7. Governing
Law. This Agreement and any claim, controversy, dispute or cause of action (whether in contract or tort or otherwise) based
upon, arising out of or relating to this Agreement and the transactions contemplated hereby and thereby shall be governed by, and
construed in accordance with, the laws of the United States and the Commonwealth of Massachusetts, without giving effect to any
choice or conflict of law provision or rule (whether of the Commonwealth of Massachusetts or any other jurisdiction).

 

[Signature page follows.]

 

    3

     

    

 

IN WITNESS
WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly
authorized as of the first date written above.

 

	 	GRANTOR:
	 	 
	 	AUGMEDIX, INC.
	 	 
	 	/s/ Emmanuel Krakaris
	 	By:	Emmanuel Krakaris
	 	Title: 	Chief Executive Officer

 

	 	LENDER:
	 	 
	 	EASTWARD FUND MANAGEMENT, LLC
	 	 	 
	 	/s/ Dennis P. Cameron
	 	By:	Dennis Cameron
	 	Title: 	Chief Executive Officer

 

     

     

    

 

EXHIBIT A

 

Copyrights

 

	Description	 	 	Registration/ Application     Number     	 	 	Registration/ Application Date   
	 	 	 	 	 	 	 
	Web Design at Augmedix.com	 	 	N/A	 	 	N/A
	 	 	 	 	 	 	 
	Software code for RDS cockpit and interface between remote document and users	 	 	N/A	 	 	N/A
	 	 	 	 	 	 	 
	Software code for Notebuilder tool	 	 	N/A	 	 	N/A

 

     

     

    

 

EXHIBIT B

 

Patents

 

	Description	 	Registration/ Application

 Number	 	 	Registration/ Application

 Date	 
	 	 	 	 	 	 	 
	System and Method for Augmenting Healthcare Provider Performance	 	 	2908/KOLNP/2015	 	 	 	January 29,  2014	 
	 	 	 	 	 	 	 	 	 
	Method of Labeling Associated Information Between Transcripts and Clinical Notes for Patient-Provider Clinic Visits	 	 	PCT/US20/456 34	 	 	 	August 10, 2020	 
	 	 	 	 	 	 	 	 	 
	System for Configuring A Natural-Language Medical Record Generation Platform	 	 	63/038,498	 	 	 	June 12, 2020	 
	 	 	 	 	 	 	 	 	 
	Natural-Language Medical Record Generation Platform	 	 	63,038,479	 	 	 	June 12, 2020	 

 

     

     

    

 

EXHIBIT C

 

Trademarks

 

	 	 	 	Registration/	 	 	Registration/
	 	 	 	Application	 	 	Application
	Description	 	 	Number	 	 	Date
	 	 	 	 	 	 	 
	(1) Augmedix Word Mark (U.S. Trademark)	 	 	Reg.  No. 4643608	 	 	November 25, 2014
	 	 	 	 	 	 	 
	(2) Augmedix Cross Logo No. 1 (U.S. Trademark)	 	 	Reg. No. 4741682	 	 	May 26, 2015
		 	 	 	 	 	 
	(3) Augmedix Cross Logo No. 2 (U.S. Trademark)	 	 	Reg. No. 6,154,047	 	 	September 15, 2020
		 	 	 	 	 	 
	(4) Augmedix Cross Logo No. 2 (India Trademark – Class 42)	 	 	App. No. 4211268	 	 	June 19, 2019
	 	 	 	 	 	 	 
	(5) Augmedix Cross Logo No. 2 (India Trademark – Class 9)	 	 	App. No. 4211265	 	 	June 19, 2019
	 	 	 	 	 	 	 

 

     

     

    

 

EXHIBIT D

 

Mask Works

 

	Description	 	Registration/ Application

 Number	 	 	Registration/ Application

 Date	 
	N/AExhibit 10.3

 

CO-INVESTMENT AGREEMENT

 

THIS CO-INVESTMENT AGREEMENT, dated as of March 25,
2021, is made by and between Eastward Fund Management, LLC, a Delaware limited liability company (“Lender”), and
Augmedix, Inc., a Delaware corporation (“Augmedix”).

 

Preliminary Statement.
Lender agreed to enter into that certain Loan and Security Agreement dated as of the date hereof (as the same may be amended, modified
or supplemented from time to time, the “Loan Agreement”) between Lender, Augmedix and Augmedix’s subsidiary,
Augmedix Operating Corporation. Unless otherwise specified, capitalized terms used herein have the definitions specified in the
Loan Agreement. Lender and Augmedix also desire to enter into this Co-Investment Agreement pursuant to which Lender and Augmedix
seek to address Lender’s right to invest in Borrower’s subsequent equity rounds.

 

Now, therefore, in
consideration of the foregoing premises and the mutual covenants contained herein and other good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, it is agreed as follows:

 

1.
Right of Lender to Participate in Subsequent Equity Financing[s] of Borrower. Upon Borrower’s execution of a
term sheet relating to Borrower’s issuance of securities (“New Securities”) to institutional, venture
capital and/or other financial investors for cash for financing purposes following the date hereof (a “New
Issuance”), Augmedix shall, as soon as possible, but in any event within five (5) Business Days prior to the completion
of the New Issuance, deliver to Lender a copy of such executed term sheet (the “Offer Notice”). For the avoidance
of doubt, Borrower’s issuance of promissory notes in connection with a bridge financing shall not be deemed to be a New
Issuance but any conversion of such promissory notes into securities shall constitute a New Issuance. In the event of a New
Issuance, Lender (or Lender’s Affiliates) shall have the right, at its election and in its sole discretion, to purchase
up to that number of New Securities in the New Issuance having an aggregate purchase price of up to $3,000,000 (if Augmedix
only draws the Initial Advance under and as defined in the Loan Agreement) or $3,400,000 (if Augmedix draws the Second
Advance under and as defined in the Loan Agreement) (the “Purchase Amount”) at the same per share purchase price
and terms upon which the New Securities are being offered to other investors in the New Issuance, such price to be paid in
full, in cash, at the time of issuance of such New Securities to Lender. For the avoidance of doubt, Lender’s rights
under this Section 1 shall terminate and be of no further force or effect upon the earliest to occur of (A) Lender has
purchased New Securities, in one or multiple transactions (whether or not related or a series), in the Purchase Amount, (B)
immediately prior to Borrower’s listing on NASDAQ or (C) immediately prior to the dissolution or winding-up of the
Company. The rights set forth in this Agreement shall be exercised by Lender, if at all, by written notice to Augmedix
delivered not later than ten (10) Business Days after the receipt by Lender of the Offer Notice in accordance with the terms
and conditions stated therein. Such equity participation right shall be exclusive of any pro-rata equity rights Lender may be
entitled to due to its investment in any of Borrower’s equity securities or upon exercise of the Warrant. The right of
Lender to purchase New Securities in a New Issuance of Augmedix as set forth above shall survive the repayment by the
Augmedix of its obligations under, or other termination of, the Loan Agreement.

 

2. Benefit
of Agreement. This Co-Investment Agreement shall be binding upon, and inure to and for the benefit of, Lender and Augmedix
and their respective successors and assigns and participants in interest. Augmedix agrees that this Co-Investment Agreement may
not be assigned by it in whole or in part without the prior written consent of Lender (not to be unreasonably withheld). Lender
agrees that, other than with respect to an Affiliate of Lender, which shall not require the prior written consent of Borrower,
this Co-Investment Agreement may not be assigned by it in whole or in part without the prior written consent of Augmedix (not to
be unreasonably withheld).

  

3. Miscellaneous.
The provisions contained in Section 12, Sections 13.7-13.8 and Sections 13.10-13.24 of the Loan Agreement (including but
not limited to, notices, choice of law and waiver of jury trial) are hereby incorporated by reference herein as if fully set forth
herein.

 

     

     

    

 

IN WITNESS WHEREOF,
the parties hereto have caused this Co-Investment Agreement to be duly executed as of the date first above written.

 

	 	Lender: Eastward Fund Management, LLC
	 	 
	 	By:	/s/ Dennis P. Cameron
	 	 	Name:  	Dennis Cameron
	 	 	Title: 	Chief Executive Officer
	 	 	 
	 	Augmedix: Augmedix, Inc.
	 	 	 
	 	By:	/s/ Emmanuel Krakaris
	 	 	Name: 	Emmanuel Krakaris
	 	 	Title: 	Chief Executive Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}]]